160 related articles for article (PubMed ID: 31431303)
1. Primary antiphospholipid syndrome presented as thrombotic microangiopathy in renal transplantation.
Bada-Bosch T; Redondo B; Sevillano AM; Alonso M; Trujillo H; Auñón P; Polanco N; Rodríguez L; Gonzalez E; Andrés A
Nefrologia (Engl Ed); 2020; 40(1):108-110. PubMed ID: 31431303
[No Abstract] [Full Text] [Related]
2. Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature.
Kello N; Khoury LE; Marder G; Furie R; Zapantis E; Horowitz DL
Semin Arthritis Rheum; 2019 Aug; 49(1):74-83. PubMed ID: 30598332
[TBL] [Abstract][Full Text] [Related]
3. Complement inhibition with eculizumab for thrombotic microangiopathy rescues a living-donor kidney transplant in a patient with antiphospholipid antibody syndrome.
Geethakumari PR; Mille P; Gulati R; Nagalla S
Transfus Apher Sci; 2017 Jun; 56(3):400-403. PubMed ID: 28428030
[TBL] [Abstract][Full Text] [Related]
4. Eculizumab therapy.
Cataland SR
Biol Blood Marrow Transplant; 2014 Apr; 20(4):438-9. PubMed ID: 24534107
[No Abstract] [Full Text] [Related]
5. The Use of Eculizumab in Tacrolimus-Induced Thrombotic Microangiopathy.
Gabr JB; Bilal H; Mirchia K; Perl A
J Investig Med High Impact Case Rep; 2020; 8():2324709620947266. PubMed ID: 32757799
[TBL] [Abstract][Full Text] [Related]
6. Thrombotic microangiopathy in the course of catastrophic antiphospholipid syndrome successfully treated with eculizumab: case report and systematic review of the literature.
Skoczynska M; Crowther MA; Chowaniec M; Ponikowska M; Chaturvedi S; Legault K
Lupus; 2020 May; 29(6):631-639. PubMed ID: 32252584
[No Abstract] [Full Text] [Related]
7. A case of thrombotic microangiopathy associated with antiphospholipid antibody syndrome successfully treated with eculizumab.
Bakhtar O; Thajudeen B; Braunhut BL; Yost SE; Bracamonte ER; Sussman AN; Kaplan B
Transplantation; 2014 Aug; 98(3):e17-8. PubMed ID: 25089339
[No Abstract] [Full Text] [Related]
8. The Role of Complement Inhibition in Thrombotic Angiopathies and Antiphospholipid Syndrome.
Erkan D; Salmon JE
Turk J Haematol; 2016 Mar; 33(1):1-7. PubMed ID: 27020721
[TBL] [Abstract][Full Text] [Related]
9. A case of thrombotic micro-angiopathy after heart transplantation successfully treated with eculizumab.
Morales E; Rabasco C; Gutierrez E; Praga M
Transpl Int; 2015 Jul; 28(7):878-80. PubMed ID: 25712140
[No Abstract] [Full Text] [Related]
10. Thrombotic Microangiopathy as a Cause of Chronic Kidney Transplant Dysfunction: Case Report Demonstrating Successful Treatment with Eculizumab.
Iqbal Z; Wood K; Carter V; Goodship TH; Brown AL; Sheerin NS
Transplant Proc; 2015 Sep; 47(7):2258-61. PubMed ID: 26361694
[TBL] [Abstract][Full Text] [Related]
11. Eculizumab deposits in vessel walls in thrombotic microangiopathy.
Cassol CA; Brodsky SV; Satoskar AA; Blissett AR; Cataland S; Nadasdy T
Kidney Int; 2019 Sep; 96(3):761-768. PubMed ID: 31345584
[TBL] [Abstract][Full Text] [Related]
12. [Eculizumab as rescue therapy for lupus nephritis-related thrombotic microangiopathy].
Fani FM; Patera A; Delsante M; Rossi GM; Manenti L; Landini S; Regolisti G; Fiaccadori E
G Ital Nefrol; 2020 Jun; 37(3):. PubMed ID: 32530153
[TBL] [Abstract][Full Text] [Related]
13. [De novo thombotic microangiopathy (TMA) after incompatible AB0 renal transplantation].
Kolb T; Rump LC
Dtsch Med Wochenschr; 2021 Apr; 146(8):530-533. PubMed ID: 33853171
[TBL] [Abstract][Full Text] [Related]
14. Patients with refractory catastrophic antiphospholipid syndrome respond inconsistently to eculizumab.
Yelnik CM; Miranda S; Mékinian A; Lazaro E; Quéméneur T; Provot F; Frimat M; Morell-Dubois S; Le Guern V; Hachulla E; Costedoat-Chalumeau N; Lambert M
Blood; 2020 Nov; 136(21):2473-2477. PubMed ID: 32722806
[No Abstract] [Full Text] [Related]
15. De novo thrombotic microangiopathy following simultaneous pancreas and kidney transplantation managed with eculizumab.
Shochet L; Kanellis J; Simpson I; Ta J; Mulley W
Nephrology (Carlton); 2017 Feb; 22 Suppl 1():23-27. PubMed ID: 28176480
[TBL] [Abstract][Full Text] [Related]
16. Thrombotic Microangiopathy Triggered by COVID-19: Case Reports.
Korotchaeva J; Chebotareva N; Andreeva E; Sorokin Y; McDonnell V; Stolyarevich E; Moiseev S
Nephron; 2022; 146(2):197-202. PubMed ID: 34808629
[TBL] [Abstract][Full Text] [Related]
17. Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab.
Ikeda T; Okumi M; Unagami K; Kanzawa T; Sawada A; Kawanishi K; Omoto K; Ishida H; Tanabe K
Nephrology (Carlton); 2016 Jul; 21 Suppl 1():35-40. PubMed ID: 26970541
[TBL] [Abstract][Full Text] [Related]
18. Eculizumab for Severe Thrombotic Microangiopathy Secondary to Surgical Invasive Stress and Bleeding.
Fujita Y; Terashita M; Yazawa M; Yamasaki Y; Imamura T; Kibayashi J; Sawai T; Hidaka Y; Ohtani K; Inoue N; Shibagaki Y
Intern Med; 2020; 59(1):93-99. PubMed ID: 31902910
[TBL] [Abstract][Full Text] [Related]
19. Thrombotic Microangiopathy in Cancer.
Weitz IC
Semin Thromb Hemost; 2019 Jun; 45(4):348-353. PubMed ID: 31041804
[TBL] [Abstract][Full Text] [Related]
20. Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes.
Canaud G; Kamar N; Anglicheau D; Esposito L; Rabant M; Noël LH; Guilbeau-Frugier C; Sberro-Soussan R; Del Bello A; Martinez F; Zuber J; Rostaing L; Legendre C
Am J Transplant; 2013 Aug; 13(8):2179-85. PubMed ID: 23763583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
